Creative Medical Technology (NASDAQ:CELZ) Announces Quarterly Earnings Results

Creative Medical Technology (NASDAQ:CELZ) posted its quarterly earnings data on Friday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02), FiscalAI reports.

Creative Medical Technology Trading Up 23.5%

Creative Medical Technology stock traded up $0.27 during mid-day trading on Friday, reaching $1.42. The company’s stock had a trading volume of 63,848,181 shares, compared to its average volume of 15,995,997. The firm has a market cap of $6.73 million, a price-to-earnings ratio of -0.66 and a beta of 1.94. The business has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.83. Creative Medical Technology has a twelve month low of $0.62 and a twelve month high of $6.25.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

Key Headlines Impacting Creative Medical Technology

Here are the key news stories impacting Creative Medical Technology this week:

• Positive Sentiment: The USPTO issued a Notice of Allowance for a patent covering exosomes from stem-cell-programmed myeloid cells. The technology is designed to promote antigen-specific immune tolerance and reduce the autoimmune destruction of insulin-producing pancreatic cells in Type 1 diabetes. The patent would strengthen protection around the MyeloCelz™ platform and complement CELZ’s CELZ-101 and CELZ-201 programs. Creative Medical patent announcement
• Positive Sentiment: Creative Medical said its intellectual-property estate now includes approximately 60 issued patents and pending applications, with plans to advance clinical programs, generate additional data and explore licensing or strategic partnerships. This gives traders a larger commercial and partnership narrative around the company’s diabetes franchise. Business Insider patent coverage
• Neutral Sentiment: Trading was halted several times under Limit Up-Limit Down rules, indicating extreme volatility. Analysts attributed the rally partly to retail momentum, CELZ’s small public float and renewed interest in earlier pipeline and financing updates rather than to new clinical results. Quiver Quantitative CELZ trading analysis
• Negative Sentiment: The patent remains investigational: a Notice of Allowance does not guarantee final issuance or meaningful commercial protection, and no MyeloCelz product has FDA approval. Clinical, regulatory and manufacturing risks remain significant.
• Neutral Sentiment: Investors are also awaiting Creative Medical’s quarterly earnings report, expected Friday. The release could provide updates on cash resources, losses and progress in the CELZ-101 and CELZ-201 programs. Expected quarterly earnings report

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.